Related by context. All words. (Click for frequent words.) 71 linaclotide treated 68 spontaneous bowel movements 67 tapentadol ER 66 oxycodone CR 65 mg BID dose 65 8mg/kg 65 Index CDAI 65 placebo p = 65 Montgomery Asberg Depression 65 ACR# ACR# 65 non menstrual pelvic 65 ADCS CGIC 65 4mg/kg 64 symptom severity 64 IRLS 64 lopinavir r arm 64 MADRS score 64 Psoriasis Area 64 OAB symptoms 64 Secondary endpoints included 63 nasal symptom 63 corticosteroid dose 63 achieved statistical significance 63 Zometa hazard 63 mcg linaclotide 63 ecchymosis 63 achieved ACR# 63 moderate renal impairment 63 Secondary endpoints include 63 mcg BID 63 peripheral sensory neuropathy 63 generalized edema 63 ACTEMRA TM 63 nausea photophobia 63 ACR# [002] 63 morphometric vertebral fractures 62 rhinorrhea 62 CSBM 62 mcg QD 62 #mg BID [001] 62 Score TOS 62 headache abdominal pain 62 CDAI score 62 quetiapine XR 62 apnea hypopnea index 62 receiving XGEVA 62 TEAEs 62 receiving golimumab 62 ug kg 62 Crohn Disease Activity 62 mcg kg REBETOL 62 GERD symptom 62 Timed Walk 62 diarrhea nausea fatigue 62 tolterodine ER 62 PANSS 62 Key secondary endpoints 62 dyspnoea 62 Rating Scale MADRS 62 CDAI 61 severe exacerbations 61 CSBMs 61 #.#/#.# mmHg [001] 61 MoxDuo TM IR 61 Fibromyalgia Impact Questionnaire 61 Global Impression CGI 61 fluticasone salmeterol 61 Score DAS 61 certolizumab 61 myalgia arthralgia 61 desvenlafaxine succinate 61 NIH CPSI 61 Inventory BPI 61 dizziness nausea diarrhea 61 tirofiban 61 primidone 61 prednisone prednisolone plus 61 budesonide formoterol 61 HAQ DI 61 placebo p 61 Alzheimer Disease Assessment 61 demonstrated clinically meaningful 61 Visual Analogue Scale VAS 61 lumbar spine BMD 61 Primary endpoints 61 mg BID 61 arthralgias 61 chills headache 61 tipranavir r 61 nasopharyngitis headache 61 gout flares 61 PASI scores 61 SSRI SNRI 61 Montgomery Åsberg Depression 61 symptomatic VTE 61 nausea somnolence 60 WOMAC pain 60 Secondary endpoints 60 Expanded Disability Status 60 phonophobia 60 IIIa inhibitor 60 plus methotrexate 60 abdominal pain flatulence 60 HAM D# 60 TAXUS p value 60 HDRS 60 MADRS 60 Severity MSCS score 60 pharyngolaryngeal pain 60 ARCALYST ® 60 Brief Psychiatric 60 PCWP 60 methotrexate monotherapy 60 somnolence dizziness 60 P = .# 60 abdominal distention 60 CI #.#-#.# [001] 60 tapentadol IR 60 Health Assessment Questionnaire 60 diarrhea dyspepsia 60 VIIBRYD 60 DAS# [002] 60 salmeterol fluticasone 60 dyspnea 60 vasomotor 60 Score DAS# 60 secondary efficacy endpoint 60 YMRS 60 â ‰ ¥ 60 prospectively stratified 60 sUA 60 mg TID 60 Mean Symptom Complex 60 mg QD 60 neutropenia thrombocytopenia 60 Unified Parkinson Disease 60 diarrhea abdominal 60 ACR# response 60 3mg/kg 60 echocardiographic parameters 60 Scale EDSS 60 dapagliflozin plus 60 PREZISTA r arm 60 IRLS score 60 left ventricular diastolic 60 CIMZIA ™ 60 SGRQ 59 serologically active patients 59 mg p = 59 CI -#.# 59 constipation dizziness 59 prespecified secondary 59 ARCOXIA 59 extrapyramidal symptoms 59 headache nasopharyngitis 59 Flu Cy 59 Scale EDSS score 59 aminotransferase elevations greater 59 constipation nausea 59 RLS symptoms 59 nasopharyngitis 59 adjunctive placebo 59 BENICAR HCT 59 pruritis 59 CorVue ™ 59 arterial thromboembolic events 59 Global Impression 59 HAMD 59 Symptom severity 59 unresectable HCC 59 ACR Pedi 59 bowel syndrome Non 59 mild renal insufficiency 59 cytogenetic response 59 IBDQ 59 dyspareunia 59 mg Proellex 59 REYATAZ r arm 59 NNT = 59 HAM D# scores 59 clinically meaningful improvement 59 serum urate 59 Severity Index PASI 59 BENICAR 59 budesonide pMDI 59 confidence interval CI 59 octreotide LAR 59 SBM frequency 59 urinary N telopeptide 59 extrapyramidal disorder 59 diarrhea flatulence 59 fatigue abdominal pain 59 UPDRS 59 pruritus itching 59 affective psychosis 59 insomnia somnolence 59 chills fever headache 59 plus MTX 59 bothersome symptom 59 nausea diarrhea fatigue 59 hip BMD 59 hypomagnesemia 59 hyperphenylalaninemia HPA due 59 Secondary efficacy endpoints 59 AGILECT ® 58 rectal tenesmus 58 p = #.# [003] 58 paresthesias 58 annualized relapse 58 -#.# mg dL [002] 58 Major Depressive Disorder MDD 58 Infusion Reactions Severe 58 ADAS cog 58 Oral Fingolimod 58 #mg/m# [001] 58 XIENCE V demonstrated 58 #mg/day [002] 58 Erythropoietic therapies may 58 headache chills 58 CIMZIA TM 58 rosuvastatin #mg 58 adjunctive ABILIFY 58 nausea emesis 58 nodular partial response 58 Visual Analog Scale 58 IBS symptoms 58 elevated ALT 58 proctitis 58 apnea hypopnea 58 alfuzosin 58 subscores 58 ARIXTRA 58 Perforomist Inhalation Solution 58 Myalgia 58 abdominal distension 58 definite stent thrombosis 58 headache diarrhea nausea 58 hypopneas 58 postoperative nausea 58 Negative Syndrome 58 binary restenosis 58 HBeAg positive patients 58 infliximab monotherapy 58 erythema redness 58 cEVR 58 ATACAND 58 CRp 58 aspirin clopidogrel 58 neutropenia dehydration dyspnea 58 severe neutropenia 58 HADS 58 TLUS 58 active ankylosing spondylitis 58 CI #.#-#.# [002] 58 MIRAPEX 58 % CI #.#-#.# [005] 58 peripheral edema 58 systemic corticosteroid 58 partial remissions 58 #mg/day [001] 58 Dyspnea 58 overactive bladder symptoms 58 fatigue asthenia 58 somnolence sleepiness 58 diarrhea nausea abdominal pain 58 baseline HbA1c 58 mg ustekinumab 58 rhinoconjunctivitis 58 plus medroxyprogesterone acetate 58 incidence ≥ 58 EFFEXOR XR 58 ACR# responses 58 NPH insulin 58 p ≤ 58 REMINYL ® 58 XIENCE V PROMUS Stent 58 epistaxis 58 receiving VICTRELIS 58 Hamilton Anxiety Scale 58 receiving PEGINTRON 58 Rating Scale UPDRS 58 fasting plasma glucose FPG 58 HBeAg negative patients 58 Ejection Fraction 58 myocardial infarction ventricular fibrillation 58 perineal pain 57 -#.# log# copies mL 57 % Confidence Interval 57 neutropaenia 57 conjunctival hyperemia 57 FOLFOX4 57 DAS# remission 57 mTSS 57 clinically meaningful improvements 57 febrile neutropenia 57 achieved PASI 57 IBS C 57 fractional shortening 57 humanized interleukin 6 57 zolmitriptan 57 pyrexia mucositis sepsis febrile 57 subsyndromal 57 nasal symptoms 57 p = NS 57 INVEGA ® 57 FluCAM arm 57 nausea constipation 57 highly emetogenic 57 constipation somnolence nausea 57 metabolic alkalosis 57 CR nPR 57 depressive symptom 57 diarrhea predominant IBS 57 MCyR 57 discomfort bloating 57 leucopenia 57 dose pravastatin 57 WOMAC 57 postoperative AF 57 p = .# [001] 57 radicular pain 57 Index CDAI score 57 refractory ischemia 57 liver histology 57 HbA 1c levels 57 events MACE 57 dizziness somnolence 57 Plaque Psoriasis 57 recurrent ischemia 57 ALT elevations 57 Keppra R 57 Intrathecal 57 EDSS score 57 hypophosphatemia 57 mCi kg 57 abdominal discomfort bloating 57 opioid induced bowel dysfunction 57 EDARBI 57 FOLFIRI alone 57 solifenacin 57 headache nausea fatigue 57 Scale PANSS 57 CIMZIA TM certolizumab pegol 57 chills fatigue 57 secondary endpoint 57 nighttime awakenings 57 % CI #.#-#.# [007] 57 Scale cognitive subscale 57 metformin IR 57 hypersomnia 57 sumatriptan naproxen sodium 57 rimonabant #mg/day 57 MACCE 57 acute postoperative 57 microgram kg 57 somatostatin analog 57 #.#mg/dL 57 TNSS 57 oral levofloxacin 57 intravaginal ejaculatory latency 57 achieving PASI 57 alanine aminotransferase ALT 57 oral diclofenac 57 UPDRS motor 57 vitreous floaters 57 Claudication 57 bronchial hyperresponsiveness 57 ALT elevation 57 PEGINTRON TM 57 somnolence headache 57 fludarabine cyclophosphamide 57 blood Phe levels 57 evaluable subjects 57 non constipation irritable 57 vaginal progesterone gel 57 death reinfarction 57 receiving FUSILEV 57 Symptom Score 57 GERD symptoms 57 HRQoL 57 arthralgia 57 oxycodone IR 57 pruritus rash 57 induce orthostatic hypotension 57 dizziness constipation 57 postintervention 57 delayed CINV 57 nonresponders 57 composite endpoint 57 QVAR ® 57 DAS# CRP 57 nocturnal awakenings 57 erosive gastritis 57 NIHSS 56 hypoglycemic events 56 weekly CSBMs 56 lopinavir r 56 p = .# [002] 56 intravascular hemolysis 56 demonstrated statistically significant 56 plus dexamethasone 56 knee osteoarthritis OA 56 unfractionated heparin UFH 56 hallucinations dyskinesia 56 confirmed CCyR 56 saline placebo 56 symptomatic NOH 56 Cilostazol 56 menopausal symptom 56 Thrombolysis 56 certolizumab pegol 56 generalized anxiety disorder GAD 56 biochemical relapse 56 venous stasis ulcers 56 scores TNSS 56 BPH Symptom Score 56 included exfoliative dermatitis 56 amoxicillin clavulanate 56 ropivacaine 56 somatic symptoms 56 epigastric pain 56 severe hypoglycemic 56 HBeAg seroconversion 56 Pain Intensity 56 zonisamide SR 56 diabetic gastroparesis 56 pruritus 56 NATRECOR ® 56 transdermal fentanyl 56 CIBIC plus 56 Platelet counts 56 CANCIDAS 56 clinically meaningful reductions 56 pooled comparator 56 mg simvastatin 56 SGPT 56 hepato renal syndrome 56 Neuropsychiatric Inventory NPI 56 Y BOCS 56 log# copies mL 56 ug dose 56 imiquimod cream 56 nonfatal MI 56 BPH symptoms 56 μg kg 56 urge urinary incontinence 56 myopathy rhabdomyolysis 56 biologic DMARD 56 nasal itching 56 microbiological eradication 56 musculoskeletal pain 56 ARB telmisartan 56 racemic albuterol 56 hives itching 56 deep venous thromboses 56 icatibant 56 nasal obstruction 56 BPS IC 56 aspirin heparin 56 adverse reactions ≥ 56 NYHA functional class 56 nausea vomiting headache 56 x ULN 56 RAPTIVA 56 headaches backaches 56 PLX STROKE targeting 56 hyperarousal 56 insulin detemir 56 μg dose 56 dysuria 56 abacavir lamivudine 56 nicardipine 56 R brand eszopiclone 56 Disease Activity 56 angioneurotic edema 56 hyperalgesia 56 transaminase elevation 56 pioglitazone HCl 56 vasomotor symptoms 56 diaphoresis 56 diarrhea nausea vomiting 56 Operative mortality 56 International Prostate Symptom 56 Lupuzor ™ 56 elevated lipase 56 -#.# log# 56 -#.# mg dL [001] 56 ULORIC 56 TMC# r 56 mL/min/#.# m2 56 titrated glipizide 56 dizziness headache nausea 56 Dysmenorrhea 56 relapsed MM 56 hyperreflexia 56 fatigue nausea vomiting 56 Events MACE 56 leukopenia 56 adefovir treated 56 chlorambucil 56 mucosal healing 56 antiemetics 56 Apidra ® 56 asthenia 56 constipation predominant IBS 56 diarrhea vomiting nausea 56 CNS LS 56 log# IU mL 56 IV bolus 56 lumbar spine bone 56 Natalizumab 56 oral corticosteroids 56 mg eq 56 Irritable Bowel Syndrome IBS 56 post herpetic neuralgia PHN 56 % CI #.#-#.# [003] 56 serum aminotransferase levels 56 Non inferiority 56 abdominal pain diarrhea nausea 56 CORDAPTIVE 56 daytime somnolence 56 anemia hemoglobin 56 #.#mmHg 56 oral prednisolone 56 episodic migraine 56 Pharmacokinetic parameters 56 BUPHENYL 56 placebo dexamethasone 56 splenectomized patients 56 CR CRu 56 % CI #.#-#.# [006] 56 acid regurgitation 56 Rate ORR 56 dysmenorrhea 56 steroid dexamethasone 56 dysesthesia 56 osteoarthritis rheumatoid arthritis 56 CCyR 56 abnormal ejaculation 56 analgesic efficacy 56 Thal Dex 56 TOVIAZ 56 venlafaxine XR 56 #mg QD [002] 56 moderately emetogenic 56 GLIADEL R Wafer 56 cough wheezing 56 lymphopenia 56 progression TTP 56 laboratory abnormalities 56 hematological adverse 56 COPD exacerbations 56 Negative Symptoms 56 Nephrol Dial Transplant 56 cognitive affective 56 mg dose 56 Mg Uk 56 UPDRS Part III 56 DPNP 56 pulmonary capillary wedge 56 discontinuations due 56 tolvaptan 55 Hazard Ratio HR 55 β blocker 55 haematologic 55 ARICEPT 55 nasopharyngitis upper 55 Relapsing Multiple Sclerosis 55 mesalamine granules 55 TNF Tumor Necrosis Factor 55 anginal pain 55 Bronchopulmonary Dysplasia 55 Hepatitis C Antiviral 55 gastrointestinal adverse reactions 55 pramipexole 55 mcg albinterferon alfa 2b 55 mg/# hours 55 CPAP adherence 55 alicaforsen enema 55 VELCADE melphalan 55 nonvertebral fracture 55 plus OBT 55 glycoprotein IIb IIIa inhibitor 55 primary generalized tonic 55 opioid analgesia 55 mcg mL 55 events AEs 55 diabetic neuropathic pain 55 serum transaminases 55 daunorubicin 55 angiographic restenosis 55 IFN alfa 55 atherothrombotic disease 55 oral FTY# 55 rheumatoid arthritis osteoarthritis ankylosing 55 ≥ 55 hemoglobin A1c HbA1c 55 somnolence fatigue 55 PROCTOCORT R 55 FFNS 55 fluoxetine paroxetine 55 muscle cramps nausea 55 treat NNT 55 DOXIL 55 ® fluocinonide Cream 55 mg tid 55 alanine aminotransferase 55 lispro 55 plasma leptin 55 Peginterferon alfa 2a 55 FOLPI 55 Skin sterol 55 SSRI citalopram 55 mucositis 55 q#h 55 constipation OIC 55 Biaxin R 55 mg qd 55 mcg kg 55 lacosamide 55 transaminases 55 teriflunomide 55 SELENA SLEDAI score 55 treatment emergent AEs 55 EURIDIS 55 aspartate aminotransferase 55 Is Well Tolerated 55 Nebulized 55 PSA nadir 55 FROVA 55 subscales 55 salmeterol inhalation powder 55 systemic embolism 55 PANSS total 55 Cholinesterase Inhibitors 55 colesevelam HCl 55 Detrol Detrol LA 55 mEq L 55 sUA levels 55 divalproex sodium 55 IELT 55 hypokalemia 55 nausea dizziness vomiting 55 Headache nausea 55 nocturia 55 postdose 55 asthenia fatigue 55 recurrent venous thromboembolism 55 left ventricular systolic 55 ADAS Cog 55 FOLFOX4 alone 55 QRS duration 55 AUA Symptom Score 55 myoclonus 55 pegylated alpha interferon 55 #mg BID [003] 55 ADCS ADL 55 Doxil ® 55 eszopiclone 55 antiarrhythmic drug 55 etanercept 55 calculated creatinine clearance 55 moderate hepatic insufficiency 55 xanthine oxidase inhibitor 55 Betaferon R 55 atrioventricular block 55 Ishak fibrosis score 55 urge incontinence 55 neuropathy sensory 55 constipation abdominal pain 55 subscale scores 55 See CLINICAL PHARMACOLOGY 55 erosive GERD 55 dose Iluvien 55 RLAI 55 Scale Cognitive Subscale 55 myalgia 55 moderate hepatic impairment 55 p = #.# [004] 55 mean baseline A1C 55 resuscitated cardiac arrest 55 bupropion SR 55 neurologic dysfunction 55 constipation IBS C 55 Response Evaluation Criteria 55 LVEF 55 mso footer margin 55 #μg [001] 55 events TEAEs 55 airflow obstruction 55 GOUT 55 bivalirudin monotherapy 55 proton pump inhibitor PPI 55 incontinence episodes 55 PsA 55 pimecrolimus cream 55 Danazol 55 Dermatologic toxicities 55 plus prednisone 55 multivariable adjusted 55 generalized tonic clonic seizures 55 trospium 55 breast tenderness bloating 55 vincristine doxorubicin 55 retinal thickness 55 comparator arm 55 FOLFIRI 55 treatment emergent adverse 55 alfa 2a 55 plus GP IIb 55 subscore 55 chronic diarrhea abdominal 55 Asacol R 55 headache myalgia 55 prolonged QT interval 55 DETROL LA 55 XIENCE V vs. 55 salmeterol fluticasone propionate 55 VaD 55 reintubation 55 pegylated interferon alfa 2b 55 COPD exacerbation 55 virologic breakthrough 55 orthostatic hypotension 55 ANCA associated 55 LEXIVA r 55 diarrhea predominant irritable 55 QTcF 55 neutropenia anemia 55 LAMICTAL 55 hematologic adverse 55 LEVAQUIN ® 55 aldosterone antagonists 55 Ischemic 55 achieved CCyR 55 baseline A1C 55 melphalan prednisone 55 oral antidiabetic medication 55 SGOT 55 6R BH4 55 nonvertebral fractures 55 erythema 55 hematological parameters 55 constipating effects 55 APTIVUS r 55 secondary efficacy endpoints 55 Numoisyn Liquid 55 Chemotherapy induced 55 sneezing itchy nose 55 D constipation predominant 55 periprocedural MI 55 mg administered orally 55 psoriatic arthritis PsA 54 irbesartan 54 urine albumin 54 ischemic cardiomyopathy 54 Functional Outcomes 54 diarrhea vomiting rash 54 HbA 1C 54 Triamcinolone 54 Pegasys ® 54 poststroke 54 placebo 54 fatal anaphylactic 54 constipation predominant 54 Adjunctive 54 hours postdose 54 See WARNINGS 54 colorectal adenoma 54 tolterodine 54 H2RAs 54 #.#g/day 54 baseline FEV 54 pregabalin 54 Hb A1C 54 activated partial thromboplastin 54 PSADT 54 detrusor overactivity 54 Non Responders 54 Generalized Anxiety Disorder 54 Castration Resistant Prostate Cancer 54 Relapsing Remitting Multiple Sclerosis 54 candesartan cilexetil 54 urate lowering therapy 54 drotrecogin alfa activated 54 confidence interval #.#-#.# 54 headache somnolence 54 coronary stenosis 54 Clin J 54 nasopharyngitis constipation dyspepsia 54 ZOMIG Nasal Spray 54 DDP# 54 HbA1C levels 54 mucosal inflammation 54 mg hydrochlorothiazide 54 GAMMAGARD 54 included neutropenia anemia 54 Exacerbations 54 fever headaches nausea 54 MAXALT 54 light headedness dizziness 54 angiotensin converting enzyme inhibitor 54 squamous histology 54 antipsychotic efficacy 54 paraesthesia 54 QTc 54 diastolic BP 54 Interferon beta 1a 54 DexaSite 54 Hypersensitivity reactions 54 EMBLEM TM 54 hypercalcemia 54 Kaplan Meier analysis 54 adalimumab 54 Physical Function 54 pregabalin Lyrica 54 gastroduodenal 54 muscle aches fatigue 54 catheter occlusion 54 paliperidone ER 54 arterial oxygen saturation 54 Raptiva r 54 glycoprotein IIb IIIa inhibitors 54 Platinol ® 54 receiving ISENTRESS 54 mmHg diastolic 54 mitoxantrone plus 54 pulmonary exacerbations 54 azilsartan medoxomil 54 Solid Tumors criteria 54 aspartate aminotransferase AST 54 plus prednisone prednisolone 54 primary efficacy endpoint 54 diameter stenosis 54 euthymic 54 bleeding pallor 54 brachial artery flow 54 Telithromycin 54 aldosterone antagonist 54 bone marrow reticulin deposition 54 gadolinium enhancing 54 primary dysmenorrhea 54 malignancy HCM 54 FluCAM 54 hepatic enzyme 54 QoL 54 stomatitis 54 TNF antagonists 54 AGILECT R 54 DAS# scores 54 SELENA SLEDAI 54 oxcarbazepine 54 nonsignificant difference 54 Q#IR 54 plus octreotide LAR 54 PREMPRO 54 % CI #.#-#.# [001] 54 thromboembolic 54 inflammatory lesions 54 serum ALT 54 nasal congestion runny nose 54 CI #.#-#.# p = 54 beclomethasone dipropionate 54 TURBT 54 interpersonal psychotherapy 54 intracranial hemorrhage ICH 54 dysmenorrhoea 54 omeprazole Prilosec 54 plus glycoprotein IIb 54 serum cortisol 54 Budesonide foam crofelemer 54 SF #v# 54 oral allopurinol 54 postprocedure 54 #mg dose [003] 54 6MWD 54 FUSILEV enhances 54 reduce serum phosphate 54 QIDS SR 54 LEXIVA 54 fluticasone furoate 54 timepoints 54 REMICADE monotherapy 54 hepatic insufficiency 54 depression irritability 54 intravitreal injections 54 SPIRIVA ® 54 liposome injection 54 zoledronate 54 oral rivaroxaban 54 hypoperfusion 54 headache vomiting 54 rufinamide 54 Score IPSS 54 heart palpitations dizziness 54 iPTH 54 metformin sulfonylurea 54 Peg IFN 54 concomitant medications 54 Bronchiectasis 54 serum HBV DNA 54 QD dosing 54 vomiting muscle aches 54 nausea vomiting cramps 54 mg/# hr 54 nadolol 54 TWYNSTA 54 confirmed thrombotic cardiovascular 54 plus ribavirin 54 virologic response 54 adenoma recurrence 54 Catheter Associated 54 overactive bladder syndrome 54 cough dyspnea 54 ribavirin RBV 54 anemia nausea 54 IOP lowering 54 angiographic outcomes 54 CIPN 54 myalgia muscle 54 levodopa carbidopa 54 Tiotropium 54 Fasting plasma glucose 54 postmenopausal osteoporotic women 54 PANSS scores 54 hypertension osteoarthritis 54 placebo PBO 54 allodynia 54 RECIST Response Evaluation Criteria 54 Lubiprostone 54 tumor progression TTP 54 preintervention 54 NMIBC 54 symptomatology 54 GI motility disorders 54 ventricular tachyarrhythmia 54 Peginterferon Alfa 2a 54 mania hypomania 54 Single Dose 54 fever aching muscles 54 clopidogrel Plavix 54 oesophagitis 54 Venous thromboembolism 54 asthenia weakness 54 symptomatic intracranial 54 methotrexate MTX 54 systolic diastolic blood 54 repeat paracentesis 54 NIS LL 54 5-FU/LV 54 metastatic carcinoid tumors 54 intermittent claudication 54 lipid lowering agents 54 levetiracetam 54 exhaled NO 54 statin monotherapy 54 LUTS 54 dalteparin 54 IFN α 54 Postoperative 54 Hematologic toxicity 54 invasive aspergillosis 54 #mg BID [002] 54 Detrol LA 54 Ocular Surface Disease 54 creatinine ratio 54 Clinician Administered PTSD 54 #μg [002] 54 dose cytarabine 54 CONCERTA ® 54 sufentanil 54 5 Fluorouracil 54 rizatriptan 54 bloating constipation 54 enthesitis 54 eplerenone 54 angioplasty stenting 54 NATRECOR R 54 erection hardness 54 Desvenlafaxine Succinate 54 myocardial reperfusion 54 airway obstruction bronchospasm stridor 54 thromboembolic events 54 plasma cortisol 54 olmesartan medoxomil hydrochlorothiazide 54 cytogenetic responses 54 naltrexone SR 54 adriamycin 54 bortezomib refractory 54 LV dysfunction 54 abdominal pain nausea 54 Traficet EN 54 symptomatic hypotension 54 PEGylated anti 53 Knodell necroinflammatory score 53 Functional Dyspepsia 53 mg RDEA# 53 Meets Primary Endpoint 53 ST Elevation Myocardial